Latest news with #GrahamRadford-Smith
Business Wire
15-05-2025
- Health
- Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients
BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) ('Microba' or the 'Company'), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. 'MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms..." Commented Associate Professor Graham Radford-Smith. These results highlight the clinical value of MetaXplore test results in advancing outcomes for patients with chronic lower gastrointestinal disorders, highlighting the potential to reshape clinical management of these conditions and set a new standard of care. An in-depth analysis of billing and claims data for MetaXplore target patient populations, has estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia. MetaXplore™ Identifies Actionable Results in the Majority of Cases Analysis conducted by Microba of 4,616 MetaXplore™ GI Plus patients test results from Australia revealed that 71.4% (3,295) of reports identified actionable results. 41.9% (1,932) of reports showed abnormal microbiome markers linked to gastrointestinal health, including 7% that were positive for a pathogen species that can cause GI abnormal microbiome markers can be addressed via evidence-based targeted nutritional or lifestyle changes, or antimicrobial therapy (antibiotics) when a pathogen is identified. 9.9% (459) of reports tested positive for a gastrointestinal marker (e.g. inflammation, pancreatic insufficiency, or faecal occult blood), prompting further diagnostic workup and supporting management of conditions such as inflammatory bowel disease (IBD), colorectal cancer, or pancreatic insufficiency via pharmacological treatment including biologics 19.6% (904) of reports tested positive for multiple markers (microbiome and gastrointestinal), addressed via a personalised mix of pharmacological, nutritional and lifestyle modification strategies These results demonstrate how the MetaXplore test provides critical new insights to enable clinicians to apply personalised, multi-dimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal disorders. In cases where no significant findings were identified, the results can help clinicians to rule out and narrow potential causes of the patients' gastrointestinal symptoms, and may suggest psychological or neurological contributors to symptoms which empower additional clinical pathways. This study is ongoing, supports the integration of MetaXplore testing into standard care protocols, and is expected to be published in peer-reviewed journals. MetaXplore™ Patients Report Measurable Health Benefits A separate study of 84 patients by Microba who received MetaXplore-guided care found that 65.5% reported health improvements after following their clinician's recommendations: 22.6% reported significant improvement 42.9% noticed some improvement These preliminary results highlight how the MetaXplore test results and personalised, targeted interventions improve patient outcomes. This initial patient survey data demonstrates the relationship between MetaXplore positive test results and improved patient outcomes, supporting the clinical impact Microba is seeing with clinicians and patients, and setting up for larger planned studies measuring patient outcomes. Associate Professor Graham Radford-Smith, a leading gastroenterologist and expert in functional GI disorders, is currently working with Microba on a clinical utility study of MetaXplore™ in his practice. He commented: 'MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms. It enables me to objectively identify microbiome dysbiosis, evaluate dietary quality, and direct patients toward evidence-based nutritional strategies. Importantly, it helps differentiate patients with normal GI and microbial profiles who may benefit from psychological support rather than further invasive testing or pharmacological escalation.' Addressable market of over 82 million patients with lower gastrointestinal symptoms An in-depth analysis of billing and claims data for MetaXplore target patient populations, estimated an addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia 1. This population consists of patients with chronic diarrhoea or non-specific abdominal symptoms such as pain, bloating and constipation, including patients characterised with Irritable Bowel Syndrome (IBS) or diagnosed with Inflammatory Bowel Disease (IBD). The current standard of care for these patients is leading to an estimated 50% of patients not getting a resolution to their symptoms 2, necessitating a radical advancement in the tools available to support these patients and improve outcomes. MetaXplore™ is supporting clinicians to manage and improve outcomes for these patients through a comprehensive test that can: Assess structural and functional abnormalities in the microbiome Detect overlooked harmful gut bacteria (pathogens), inflammatory or insufficiency markers Identify evidence based, personalised pharmacological, nutritional and lifestyle modification strategies Support patient motivation and adherence to pharmacological, nutritional and lifestyle modifications May support identification of cases where mental health support may be appropriate As the burden of chronic digestive disorders continues to grow, MetaXplore offers a scalable, evidence-based new solution to evaluate and clinically manage GI dysfunction. About Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
AFP
29-04-2025
- Health
- AFP
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
Microba Life Sciences Limited (ASX: MAP) ('Microba') a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one of Australia's leading gastroenterology services. This press release features multimedia. View the full release here: Transforming IBD Care: MetaPanel™ Demonstrates High Clinical Utility Two independent clinical studies led by renowned Australian gastroenterologists Associate Professor Jake Begun and Associate Professor Graham Radford-Smith have demonstrated compelling clinical utility for Microba's MetaPanel™ in the management of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. The studies found that: 40% of IBD patients experiencing a disease flare were positive for a gastrointestinal (GI) pathogen, and More than 60% of these pathogens would be missed using current routine testing methods These results provide critical new insights for the clinical management of IBD patients, support the integration of MetaPanel testing into standard care protocols, and are expected to be published in peer-reviewed journals. Detecting a treatable GI pathogen during flare episodes may provide a more effective path to remission, helping clinicians avoid unnecessary therapeutic escalation, reduce the risk of treatment failure, and minimise the need for surgical interventions. Associate Professor Graham Radford-Smith, one of Australia's leading experts in Inflammatory Bowel Disease, commented: 'These results are compelling, both as a clinical use case for MetaPanel, and for the future of precision medicine in gastroenterology. For clinicians like myself managing complex IBD cases, the ability to detect pathogens missed by routine testing could transform how patients are treated — with the potential to avoid the side effects of unnecessary therapeutic escalation, enhance responsiveness to IBD therapies, and ultimately improve patient outcomes.' Partnership with Colonoscopy Clinic and Integrated Gut Health to Deliver Real-World Impact Microba has also entered a clinical partnership with the Colonoscopy Clinic, a leading Australian private gastroenterology service that sees more than 10,000 patients annually. Under the agreement, Microba and the Colonoscopy Clinic will collaborate to integrate MetaPanelTM and MetaXploreTM testing into clinical protocols for their patients. Key elements of the partnership include: Routine use of MetaPanel and MetaXplore to support diagnosis and treatment decision-making Joint clinical research and publication efforts to quantify the impact of Microba diagnostic tests on patient outcomes Development of a next-generation gastroenterology care model centred on Microba's precision diagnostics. The partnership aligns with Microba's vision to enable precision microbiome-based diagnostic testing to transform the standard of care for patients with gastrointestinal disorders. Associate Professor Dan Worthley, Gastroenterologist at Colonoscopy Clinic, commented: 'We're seeing an increasing number of patients with chronic and complex gastrointestinal symptoms where standard testing and colonoscopy isn't giving us the full picture. Microba's testing provides a new lens into hidden pathogens, the microbiome and gastrointestinal function which is delivering new outcomes for patients. Partnering with Microba enables us to lead a shift in Gastroenterology practice toward more precise, data-driven care—and ultimately better outcomes for our patients.' A Compelling Commercial Opportunity With over 7 million people globally affected by IBD and a growing recognition of the microbiome's role in disease management, MetaPanel™ offers a differentiated, clinically validated tool for identifying actionable contributors to flare. Microba is uniquely positioned to drive the adoption of this advanced testing approach, with major centres of gastroenterology excellence like the Colonoscopy Clinic. About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. View source version on For further information, please contact: investor@ © Business Wire, Inc. Haftungsausschluss : Diese Pressemitteilung ist kein von AFP erstelltes Dokument. AFP übernimmt keine Verantwortung für ihren Inhalt. Bei Fragen wenden Sie sich bitte an die im Text der Pressemitteilung genannten Kontaktpersonen/Stellen.
Yahoo
29-04-2025
- Health
- Yahoo
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
Two independent clinical studies have demonstrated that Microba's MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods. These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery. Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia's largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes. BRISBANE, Australia, April 29, 2025--(BUSINESS WIRE)--Microba Life Sciences Limited (ASX: MAP) ("Microba") a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one of Australia's leading gastroenterology services. Transforming IBD Care: MetaPanel™ Demonstrates High Clinical Utility Two independent clinical studies led by renowned Australian gastroenterologists Associate Professor Jake Begun and Associate Professor Graham Radford-Smith have demonstrated compelling clinical utility for Microba's MetaPanel™ in the management of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. The studies found that: 40% of IBD patients experiencing a disease flare were positive for a gastrointestinal (GI) pathogen, and More than 60% of these pathogens would be missed using current routine testing methods These results provide critical new insights for the clinical management of IBD patients, support the integration of MetaPanel testing into standard care protocols, and are expected to be published in peer-reviewed journals. Detecting a treatable GI pathogen during flare episodes may provide a more effective path to remission, helping clinicians avoid unnecessary therapeutic escalation, reduce the risk of treatment failure, and minimise the need for surgical interventions. Associate Professor Graham Radford-Smith, one of Australia's leading experts in Inflammatory Bowel Disease, commented: "These results are compelling, both as a clinical use case for MetaPanel, and for the future of precision medicine in gastroenterology. For clinicians like myself managing complex IBD cases, the ability to detect pathogens missed by routine testing could transform how patients are treated — with the potential to avoid the side effects of unnecessary therapeutic escalation, enhance responsiveness to IBD therapies, and ultimately improve patient outcomes." Partnership with Colonoscopy Clinic and Integrated Gut Health to Deliver Real-World Impact Microba has also entered a clinical partnership with the Colonoscopy Clinic, a leading Australian private gastroenterology service that sees more than 10,000 patients annually. Under the agreement, Microba and the Colonoscopy Clinic will collaborate to integrate MetaPanelTM and MetaXploreTM testing into clinical protocols for their patients. Key elements of the partnership include: Routine use of MetaPanel and MetaXplore to support diagnosis and treatment decision-making Joint clinical research and publication efforts to quantify the impact of Microba diagnostic tests on patient outcomes Development of a next-generation gastroenterology care model centred on Microba's precision diagnostics. The partnership aligns with Microba's vision to enable precision microbiome-based diagnostic testing to transform the standard of care for patients with gastrointestinal disorders. Associate Professor Dan Worthley, Gastroenterologist at Colonoscopy Clinic, commented: "We're seeing an increasing number of patients with chronic and complex gastrointestinal symptoms where standard testing and colonoscopy isn't giving us the full picture. Microba's testing provides a new lens into hidden pathogens, the microbiome and gastrointestinal function which is delivering new outcomes for patients. Partnering with Microba enables us to lead a shift in Gastroenterology practice toward more precise, data-driven care—and ultimately better outcomes for our patients." A Compelling Commercial Opportunity With over 7 million people globally affected by IBD and a growing recognition of the microbiome's role in disease management, MetaPanel™ offers a differentiated, clinically validated tool for identifying actionable contributors to flare. Microba is uniquely positioned to drive the adoption of this advanced testing approach, with major centres of gastroenterology excellence like the Colonoscopy Clinic. About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. View source version on Contacts For further information, please contact:investor@ Sign in to access your portfolio
National Post
29-04-2025
- Health
- National Post
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
Article content Two independent clinical studies have demonstrated that Microba's MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods. These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery. Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia's largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes. Article content Article content BRISBANE, Australia — Microba Life Sciences Limited (ASX: MAP) ('Microba') a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one of Australia's leading gastroenterology services. Article content Transforming IBD Care: MetaPanel™ Demonstrates High Clinical Utility Article content Two independent clinical studies led by renowned Australian gastroenterologists Associate Professor Jake Begun and Associate Professor Graham Radford-Smith have demonstrated compelling clinical utility for Microba's MetaPanel™ in the management of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. Article content The studies found that: Article content These results provide critical new insights for the clinical management of IBD patients, support the integration of MetaPanel testing into standard care protocols, and are expected to be published in peer-reviewed journals. Detecting a treatable GI pathogen during flare episodes may provide a more effective path to remission, helping clinicians avoid unnecessary therapeutic escalation, reduce the risk of treatment failure, and minimise the need for surgical interventions. Article content Associate Professor Graham Radford-Smith, one of Australia's leading experts in Inflammatory Bowel Disease, commented: Article content 'These results are compelling, both as a clinical use case for MetaPanel, and for the future of precision medicine in gastroenterology. For clinicians like myself managing complex IBD cases, the ability to detect pathogens missed by routine testing could transform how patients are treated — with the potential to avoid the side effects of unnecessary therapeutic escalation, enhance responsiveness to IBD therapies, and ultimately improve patient outcomes.' Article content Microba has also entered a clinical partnership with the Colonoscopy Clinic, a leading Australian private gastroenterology service that sees more than 10,000 patients annually. Under the agreement, Microba and the Colonoscopy Clinic will collaborate to integrate MetaPanel TM and MetaXplore TM testing into clinical protocols for their patients. Article content Key elements of the partnership include: Article content Routine use of MetaPanel and MetaXplore to support diagnosis and treatment decision-making Joint clinical research and publication efforts to quantify the impact of Microba diagnostic tests on patient outcomes Development of a next-generation gastroenterology care model centred on Microba's precision diagnostics. Article content The partnership aligns with Microba's vision to enable precision microbiome-based diagnostic testing to transform the standard of care for patients with gastrointestinal disorders. Article content Associate Professor Dan Worthley, Gastroenterologist at Colonoscopy Clinic, commented: Article content 'We're seeing an increasing number of patients with chronic and complex gastrointestinal symptoms where standard testing and colonoscopy isn't giving us the full picture. Microba's testing provides a new lens into hidden pathogens, the microbiome and gastrointestinal function which is delivering new outcomes for patients. Partnering with Microba enables us to lead a shift in Gastroenterology practice toward more precise, data-driven care—and ultimately better outcomes for our patients.' Article content With over 7 million people globally affected by IBD and a growing recognition of the microbiome's role in disease management, MetaPanel™ offers a differentiated, clinically validated tool for identifying actionable contributors to flare. Microba is uniquely positioned to drive the adoption of this advanced testing approach, with major centres of gastroenterology excellence like the Colonoscopy Clinic. Article content Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. Article content Article content Article content Article content Article content
Business Wire
29-04-2025
- Health
- Business Wire
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner
BRISBANE, Australia--(BUSINESS WIRE)-- Microba Life Sciences Limited (ASX: MAP) ('Microba') a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one of Australia's leading gastroenterology services. Transforming IBD Care: MetaPanel™ Demonstrates High Clinical Utility Two independent clinical studies led by renowned Australian gastroenterologists Associate Professor Jake Begun and Associate Professor Graham Radford-Smith have demonstrated compelling clinical utility for Microba's MetaPanel™ in the management of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. The studies found that: 40% of IBD patients experiencing a disease flare were positive for a gastrointestinal (GI) pathogen, and More than 60% of these pathogens would be missed using current routine testing methods These results provide critical new insights for the clinical management of IBD patients, support the integration of MetaPanel testing into standard care protocols, and are expected to be published in peer-reviewed journals. Detecting a treatable GI pathogen during flare episodes may provide a more effective path to remission, helping clinicians avoid unnecessary therapeutic escalation, reduce the risk of treatment failure, and minimise the need for surgical interventions. Associate Professor Graham Radford-Smith, one of Australia's leading experts in Inflammatory Bowel Disease, commented: 'These results are compelling, both as a clinical use case for MetaPanel, and for the future of precision medicine in gastroenterology. For clinicians like myself managing complex IBD cases, the ability to detect pathogens missed by routine testing could transform how patients are treated — with the potential to avoid the side effects of unnecessary therapeutic escalation, enhance responsiveness to IBD therapies, and ultimately improve patient outcomes.' Partnership with Colonoscopy Clinic and Integrated Gut Health to Deliver Real-World Impact Microba has also entered a clinical partnership with the Colonoscopy Clinic, a leading Australian private gastroenterology service that sees more than 10,000 patients annually. Under the agreement, Microba and the Colonoscopy Clinic will collaborate to integrate MetaPanel TM and MetaXplore TM testing into clinical protocols for their patients. Key elements of the partnership include: Routine use of MetaPanel and MetaXplore to support diagnosis and treatment decision-making Joint clinical research and publication efforts to quantify the impact of Microba diagnostic tests on patient outcomes Development of a next-generation gastroenterology care model centred on Microba's precision diagnostics. The partnership aligns with Microba's vision to enable precision microbiome-based diagnostic testing to transform the standard of care for patients with gastrointestinal disorders. Associate Professor Dan Worthley, Gastroenterologist at Colonoscopy Clinic, commented: 'We're seeing an increasing number of patients with chronic and complex gastrointestinal symptoms where standard testing and colonoscopy isn't giving us the full picture. Microba's testing provides a new lens into hidden pathogens, the microbiome and gastrointestinal function which is delivering new outcomes for patients. Partnering with Microba enables us to lead a shift in Gastroenterology practice toward more precise, data-driven care—and ultimately better outcomes for our patients.' A Compelling Commercial Opportunity With over 7 million people globally affected by IBD and a growing recognition of the microbiome's role in disease management, MetaPanel™ offers a differentiated, clinically validated tool for identifying actionable contributors to flare. Microba is uniquely positioned to drive the adoption of this advanced testing approach, with major centres of gastroenterology excellence like the Colonoscopy Clinic. About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
